Informed Medical Communications (IMC) a healthcare communications and training provider, has merged with training program designer and developer, IC Axon.
PsiOxus Therapeutics has predicted growing demand for oncolytic vaccines, citing recent industry acquisitions as evidence of the need for novel treatments for cancer.
Drug industry demand for chemical intermediates and development projects has rebounded significantly in the last 12 months according to UK group Endeavour Specialty Chemicals.
Hospira has acquired the worldwide rights to filgrastim and a Croatian biologics plant from Pliva, increasing its presence in the biogenerics field, and told in-PharmaTechnologist that further expansions are possible.
Canadian contractor Patheon has welcomed the $460m (€321m) takeover offer from Switzerland's Lonza that could, according to some observers, spark a bidding war with rival suitor, US group JLL Patheon Holdings.
IT solutions firm Merge Healthcare has won the race to buy eClinical specialist etrials, beating previous suitor Bio-Imaging Technologies whose takeover bid collapsed on Monday.
Clinical research organisation Encorium has postponed the release of its third quarter results but said it still expects the figures to be in line with its most up-to-date guidance.
Encorium Group has just announced its intention to acquire an
oncology-focused contract research organisation (CRO), along with
plans to merge with another entity that will offer it a wider
global reach.
German firm Sartorius has merged its biotech unit with
biopharmaceutical supplier Stedim Biosystems, forming a company
anticipated to generate sales of €400-420m during 2007.
Separations specialist Whatman is starting to reap the benefits of
its acquisition of Schleicher & Schuell, but had a difficult
first half to the year with the group's combined revenues down
marginally compared to first-half...
According to new data, venture capital funding is on a downswing
with a demand for acquisitions shifting in the pharmaceutical
sector. The news could signal a trend towards the acquisition of
compounds, rights, licenses and product...
Fisher Scientific and Apogent Technologies are to merge in a $3.7
billion (€3.01bn) deal that will double Fisher's footprint in the
high-growth life sciences equipment market, reports Phil
Taylor.
Israel-headquartered generics company Teva Pharmaceutical
Industries has completed its $3.4 billion takeover of US company
SICOR, which makes generics and active pharmaceutical ingredients.
After Amersham confirmed yesterday that it had received a bid from
an unnamed suitor wishing to buy the entire company, its shares
rose more than 16 per cent; both J&J and Roche are in the
rumour mill.
Pharmaceutical company mergers and acquisitions plus industry-wide
cost cutting has squeezed investment into manufacturing, which may
lead to GMP non-compliance and fines, warns a new report.
Spotlight on the home of the celebrated pork pie in England, with
the annoucement this week that Melton Mowbray-based Bridgehead
Technologies and Pharmalicensing - two biopharmaceutical business
development companies - are to merge.
